Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-03-24

FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for LAMICTAL XR (lamotrigine) filed by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LAMICTAL XR (lamotrigine)

Snippet

SUPPL AP for LAMICTAL XR (LAMOTRIGINE)